The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Press release from PR Newswire

Regeneron to Report Fourth Quarter and Full Year 2012 Financial and Operating Results and Host Conference Call and Webcast on February 14, 2013

Monday, January 28, 2013

Regeneron to Report Fourth Quarter and Full Year 2012 Financial and Operating Results and Host Conference Call and Webcast on February 14, 201316:05 EST Monday, January 28, 2013TARRYTOWN, N.Y., Jan. 28, 2013 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced that it will report its fourth quarter and full year 2012 financial and operating results on Thursday, February 14, 2013, before the U.S. financial markets open.  The Company will host a conference call and simultaneous webcast at 8:30 AM EST that day. Conference Call InformationTo access this call, dial (888) 660-6127 (U.S.) or (973) 890-8355 (International).  A link to the webcast may be accessed from the 'Events and Presentations' page of Regeneron's website at www.regeneron.com.  A replay of the conference call and webcast will be archived on the Company's website and will be available for 30 days.  About Regeneron Pharmaceuticals, Inc.Regeneron is a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.  Regeneron markets medicines for eye diseases, colorectal cancer, and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including hypercholesterolemia, rheumatoid arthritis, and asthma.  For additional information about the company, please visit www.regeneron.com.Contact Information:Michael Aberman, M.D.Peter DworkinInvestor RelationsCorporate Communications                                914-847-7799914.847.7640                 michael.aberman@regeneron.competer.dworkin@regeneron.com SOURCE Regeneron Pharmaceuticals, Inc.